Cynata Therapeutics Limited
CYP.ASXHealth Care
Clinical stage biotechnology company specialising in cell therapeutics
Market Data
$0.012
-0.1%$3.2M
-100000.0x
$-0.037
0.00%
-0.9%
Latest Earnings
Appendix 4D & Half-Year Financial Statements
26 February 2026
Cynata Therapeutics reported a reduced loss of $2.7M for H1 FY2026, improving from $3.6M in the prior corresponding period, despite revenue declining 10% to $1.8M. The company closed the half with $2.6M cash and has since raised an additional $1.2M via its ATM facility, providing a runway into mid-2026 while awaiting critical Phase 3 osteoarthritis and Phase 2 aGvHD trial results expected in Q2 2026. Key points: Phase 3 osteoarthritis trial completed final patient visits - results expected Q2 2026; Phase 2 aGvHD trial completed patient enrollment with 65 participants - results expected June 2026; Strengthened intellectual property portfolio with several patent allowances in US and Europe
Recent Announcements
Ceasing to be a substantial holder
FIL Limited and its entities listed in Annexure A ("FIL") ceased to be a substantial holder.
Becoming a substantial holder
Hugh Pilgrim became a substantial holder of Cynata Therapeutics Limited on 26 June 2026, acquiring 16,703,923 fully paid ordinary shares (6.86% voting power) through himself and associated entity Annbrook Capital Pty Ltd, which together hold 19,903,923 shares.
Ceasing to be a substantial holder
Phillip Asset Management Ltd atf Bioscience Managers Translation Fund 1 ceased to be a substantial holder.
Appendix 4D & Half-Year Financial Statements
Cynata Therapeutics reported a reduced loss of $2.7M for H1 FY2026, improving from $3.6M in the prior corresponding period, despite revenue declining 10% to $1.8M. The company closed the half with $2.6M cash and has since raised an additional $1.2M via its ATM facility, providing a runway into mid-2026 while awaiting critical Phase 3 osteoarthritis and Phase 2 aGvHD trial results expected in Q2 2026. Key points: Phase 3 osteoarthritis trial completed final patient visits - results expected Q2 2026; Phase 2 aGvHD trial completed patient enrollment with 65 participants - results expected June 2026; Strengthened intellectual property portfolio with several patent allowances in US and Europe
Get real-time alerts for CYP
Receive AI-powered earnings summaries and instant notifications when Cynata Therapeutics Limited releases results.
Register Free